Artiva Biotherapeutics
ARTV
48 hedge funds and large institutions have $27.9M invested in Artiva Biotherapeutics in 2025 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 16 reducing their positions, and 17 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 53 → 48 (-5)
9.91% less ownership
Funds ownership: 85.88% → 75.97% (-9.9%)
29% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 17
44% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 16
55% less capital invested
Capital invested by funds: $62.8M → $27.9M (-$34.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$687K |
| 2 |
HF
HRT Financial
New York
|
+$163K |
| 3 |
Goldman Sachs
New York
|
+$160K |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$110K |
| 5 |
Jane Street
New York
|
+$92.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$2.6M |
| 2 |
BlackRock
New York
|
-$1.6M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.31M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$528K |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$435K |
ARTV Hedge Fund Activity: Q2 2025 in Review
48 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Artiva Biotherapeutics (ARTV) for Q2 2025, worth a combined $27.9M — down 55% from $62.8M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ARTV and 12 opened new positions — a net loss of 5 holders — while 16 trimmed existing stakes and 9 added.
The largest buyer was Millennium Management, opening a new position worth an estimated $687K. The largest seller was Capital World Investors, exiting entirely with an estimated $2.6M sold.
- 48 institutional investors held Artiva Biotherapeutics (ARTV) as of Q2 2025, down from 53 in Q1 2025.
- Funds reported $27.9M of Artiva Biotherapeutics stock for Q2 2025, down 55% quarter-over-quarter.
- 12 funds opened new Artiva Biotherapeutics positions in Q2 2025 and 17 closed out, a net change of -5 holders.
- The largest Artiva Biotherapeutics buyer in Q2 2025 was Millennium Management, an estimated $687K added.
- The largest Artiva Biotherapeutics seller in Q2 2025 was Capital World Investors, an estimated $2.6M sold.
Based on aggregated 13F filings for Q2 2025.